United Therapeutics Corporation (UTHR) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
UTHR's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
UTHR Revenue Analysis (2014–2025)
As of February 28, 2026, United Therapeutics Corporation (UTHR) generated trailing twelve-month (TTM) revenue of $3.18 billion, reflecting solid growth of +7.4% year-over-year. The most recent quarter (Q4 2025) recorded $790.2 million in revenue, down 1.2% sequentially.
Looking at the longer-term picture, UTHR's 5-year compound annual growth rate (CAGR) stands at +16.5%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $3.18 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows UTHR's business is primarily driven by Tyvaso (59%), Remodulin (17%), and Orenitram (16%). With over half of revenue concentrated in Tyvaso, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ZLAB (+15.3% YoY), AMRN (-6.2% YoY), and ALKS (-5.2% YoY), UTHR has underperformed the peer group in terms of revenue growth. Compare UTHR vs ZLAB →
Peer Comparison
Compare UTHR's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| UTHRCurrent | $3.2B | +7.4% | +16.5% | 46.9% | |
| ZLAB | $460M | +15.3% | +56.5% | -49.9% | |
| AMRN | $229M | -6.2% | -11.9% | -40.2% | |
| ALKS | $1.5B | -5.2% | +7.3% | 17.2% | |
| ADMA | $426M | +27.6% | +70.8% | 32.6% | |
| ARQT | $376M | +91.3% | - | -3.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.18B | +10.6% | $2.80B | 87.9% | $1.49B | 46.9% |
| 2024 | $2.88B | +23.6% | $2.57B | 89.2% | $1.38B | 47.9% |
| 2023 | $2.33B | +20.2% | $2.07B | 88.9% | $1.18B | 50.9% |
| 2022 | $1.94B | +14.9% | $1.79B | 92.4% | $979.7M | 50.6% |
| 2021 | $1.69B | +13.6% | $1.56B | 92.7% | $555.9M | 33.0% |
| 2020 | $1.48B | +2.4% | $1.38B | 92.7% | $593.6M | 40.0% |
| 2019 | $1.45B | -11.0% | $1.33B | 91.9% | $-187,600,000 | -12.9% |
| 2018 | $1.63B | -5.7% | $1.43B | 87.8% | $805.4M | 49.5% |
| 2017 | $1.73B | +7.9% | $1.62B | 93.9% | $814.9M | 47.2% |
| 2016 | $1.60B | +9.1% | $1.53B | 95.5% | $1.06B | 66.4% |
See UTHR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs UTHR Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare UTHR vs AGIO
See how UTHR stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is UTHR's revenue growth accelerating or slowing?
UTHR maintains +7.4% revenue growth, in line with its 5-year CAGR of +16.5%. TTM revenue stands at $3.2B. Growth rate remains consistent with historical average.
What is UTHR's long-term revenue growth rate?
United Therapeutics Corporation's 5-year revenue CAGR of +16.5% reflects the sustained expansion pattern. Current YoY growth of +7.4% is near this long-term average.
How is UTHR's revenue distributed by segment?
UTHR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.